Moreover, the authors observed significant upregulation of PD-L1 expression in the glioma cells following this regimen, so they added anti-PDL-1 immune checkpoint blockade to the therapy, resulting in complete tumor regression in 60% of animals bearing mIDH1 glioma. This evidence concerns the gene CD274 and neoplasm.